Publications by the researcher in collaboration with Carmen Fajardo Montañana (24)

2024

  1. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  2. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  3. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  4. Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433

  5. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

  6. Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects

    Diabetes Therapy, Vol. 15, Núm. 7, pp. 1501-1512

2023

  1. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Data mining analyses for precision medicine in acromegaly: a proof of concept

    Scientific Reports, Vol. 12, Núm. 1

  2. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819

  2. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

    The Lancet, Vol. 398, Núm. 10313, pp. 1811-1824

2020

  1. Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey

    Pituitary, Vol. 23, Núm. 2, pp. 129-139

  2. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

    Endocrine, Vol. 70, Núm. 3, pp. 575-583

  3. Molecular profiling for acromegaly treatment: a validation study

    Endocrine-related cancer, Vol. 27, Núm. 6, pp. 375-389

2019

  1. Strategic reflections of the Spanish Society of Endocrinology and Nutrition on the future of the speciality in the period 2018-2022

    Endocrinologia, Diabetes y Nutricion, Vol. 66, Núm. 10, pp. 654-662

2018

  1. Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus

    Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 5, pp. 297-305

2017

  1. Prevalence of acromegaly in patients with symptoms of sleep apnea

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. El Registro Molecular de Adenomas Hipofisarios (REMAH): una apuesta de futuro de la Endocrinología española por la medicina individualizada y la investigación traslacional

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 6, pp. 274-284

  2. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408

2014

  1. Documento de consenso del área de conocimiento de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición para el abordaje del hipopituitarismo durante la transición

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 61, Núm. 2, pp. 1001-1011